Investment Thesis
OrthoPediatrics demonstrates solid revenue growth (15.4% YoY) and excellent gross margins (73.1%), but is fundamentally unprofitable with operating losses of $8.3M and deteriorating net losses of $10.7M despite topline expansion. Negative operating cash flow (-$3.3M) and negative free cash flow (-$5.0M) indicate the company is burning cash while growing, and the $12.2M cash balance provides only ~1 year of runway at current burn rates.
Strengths
- Strong revenue growth of 15.4% YoY demonstrates market traction in medical devices
- Excellent gross margin of 73.1% indicates strong product pricing power and manufacturing efficiency
- Solid balance sheet with $502.2M in assets and reasonable debt-to-equity ratio of 0.31x
Risks
- Operating losses of $8.3M (-14% margin) and net losses of $10.7M (-18% margin) indicate unprofitable operations
- Negative operating cash flow (-$3.3M) and free cash flow (-$5.0M) show the company is burning cash despite revenue growth
- Critically low cash position of $12.2M relative to annual losses creates urgent capital raise risk within 12-18 months
- Deteriorating profitability with net losses worsening 4.8% YoY even as revenue grows, suggesting scale is not improving unit economics
Key Metrics to Watch
- Operating cash flow trend - must turn positive to validate business model sustainability
- Cash balance and burn rate - critical to determine capital raise timing and dilution risk
- Path to operating profitability - need clear evidence of margin expansion from revenue growth
Financial Metrics
Revenue
59.4M
Net Income
-10.7M
EPS (Diluted)
$-0.45
Free Cash Flow
-5.0M
Total Assets
502.2M
Cash
12.2M
Profitability Ratios
Gross Margin
73.1%
Operating Margin
-14.0%
Net Margin
-18.0%
ROE
-3.2%
ROA
-2.1%
FCF Margin
-8.5%
Balance Sheet & Liquidity
Current Ratio
5.21x
Quick Ratio
2.37x
Debt/Equity
0.31x
Debt/Assets
32.6%
Interest Coverage
-4.96x
Long-term Debt
106.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:03:37.694048 |
Data as of: 2026-03-31 |
Powered by Claude AI